MCID: VLV010
MIFTS: 45

Vulvovaginitis

Categories: Reproductive diseases

Aliases & Classifications for Vulvovaginitis

MalaCards integrated aliases for Vulvovaginitis:

Name: Vulvovaginitis 12 72 51 41 14 69
Vulvo-Vaginitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2273
ICD10 32 N76.0
MeSH 41 D014848
NCIt 46 C35131
UMLS 69 C0042998

Summaries for Vulvovaginitis

MalaCards based summary : Vulvovaginitis, also known as vulvo-vaginitis, is related to bacterial vaginosis and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity. An important gene associated with Vulvovaginitis is HSPD1 (Heat Shock Protein Family D (Hsp60) Member 1), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Miconazole and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and neutrophil.

Wikipedia : 72 Vaginitis is inflammation of the vagina. In most cases, it is a symptom of an infection of the... more...

Related Diseases for Vulvovaginitis

Diseases related to Vulvovaginitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 bacterial vaginosis 30.4 CXCL8 IL10
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 29.7 HSPD1 IL10
3 esophagitis 29.6 CCL11 CXCL8
4 oral lichen planus 29.4 CCL5 HSPD1
5 peritonitis 29.3 CXCL8 IL10
6 chlamydia 29.2 CXCL8 HSPD1 IL10
7 allergic hypersensitivity disease 29.0 CCL11 CCL5 IL10
8 rhinitis 28.9 CCL11 CCL5 CXCL8
9 human immunodeficiency virus type 1 28.7 CCL11 CCL5 IL10
10 psoriasis 28.5 CCL5 CXCL8 IL10
11 vulvovaginal candidiasis 12.5
12 vulvovaginal gingival syndrome 12.1
13 vulvovaginal rhabdomyosarcoma 12.0
14 vulvovaginitis, allergic seminal 11.9
15 vaginitis 11.4
16 vulvitis 11.2
17 vulvar vestibulitis syndrome 11.2
18 vulvar disease 11.1
19 candidiasis 10.9
20 postmenopausal atrophic vaginitis 10.9
21 carrion's disease 10.3 CCL11 HSPD1
22 mycobacterium fortuitum 10.3 CXCL8 HSPD1
23 papillary conjunctivitis 10.2 CCL11 CXCL8
24 giant papillary conjunctivitis 10.2 CCL11 CXCL8
25 allergic conjunctivitis 10.2 CCL11 CXCL8
26 trachoma 10.2 HSPD1 IL10
27 lichen planus 10.2
28 mixed connective tissue disease 10.1 HSPD1 IL10
29 reactive arthritis 10.1 HSPD1 IL10
30 conjunctivitis 10.1 CCL11 CXCL8
31 gingivitis 10.1
32 keratoconjunctivitis 10.1 CCL11 CXCL8
33 leprosy 3 10.1 HSPD1 IL10
34 tungiasis 10.1 CXCL8 IL10
35 acute transverse myelitis 10.1 CXCL8 IL10
36 pouchitis 10.1 CXCL8 IL10
37 necatoriasis 10.1 CXCL8 IL10
38 funisitis 10.1 CXCL8 IL10
39 trichuriasis 10.1 CXCL8 IL10
40 clonorchiasis 10.1 CXCL8 IL10
41 retinitis pigmentosa 44 10.1 CXCL8 IL10
42 transverse myelitis 10.1 CXCL8 IL10
43 candida glabrata 10.1
44 aseptic meningitis 10.1 CXCL8 IL10
45 primary peritoneal carcinoma 10.1 CXCL8 IL10
46 cytomegalovirus infection 10.1 CXCL8 IL10
47 acute pyelonephritis 10.1 CXCL8 IL10
48 prostatitis 10.1 CXCL8 IL10
49 leptospirosis 10.1 CXCL8 IL10
50 primary bacterial infectious disease 10.1 HSPD1 IL10

Graphical network of the top 20 diseases related to Vulvovaginitis:



Diseases related to Vulvovaginitis

Symptoms & Phenotypes for Vulvovaginitis

Drugs & Therapeutics for Vulvovaginitis

Drugs for Vulvovaginitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
2
Fluconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86386-73-4 3365
3
Clotrimazole Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 23593-75-1 2812
4
Dequalinium Approved, Investigational Phase 4 6707-58-0
5
Terconazole Approved Phase 4 67915-31-5 441383
6
Clindamycin Approved, Vet_approved Phase 4,Phase 3 18323-44-9 29029
7
Ephedrine Approved Phase 4 299-42-3 9294
8
Pseudoephedrine Approved Phase 4 90-82-4 7028
9 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
16 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
17 Anti-Infective Agents, Local Phase 4,Phase 3
18 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3
19 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
20 Clindamycin palmitate Phase 4,Phase 3
21 Clindamycin phosphate Phase 4,Phase 3
22 Tetrahydrozoline Phase 4,Phase 3
23 Antibiotics, Antitubercular Phase 4
24 Antitubercular Agents Phase 4
25 Autonomic Agents Phase 4
26 Nasal Decongestants Phase 4
27 Ophthalmic Solutions Phase 4
28 Peripheral Nervous System Agents Phase 4
29 Pharmaceutical Solutions Phase 4,Phase 2
30 Respiratory System Agents Phase 4
31 Vasoconstrictor Agents Phase 4
32
Butoconazole Approved Phase 3 64872-76-0, 64872-77-1 47472
33
Amphotericin B Approved, Investigational Phase 3,Phase 2 1397-89-3 5280965 14956
34
Ketoconazole Approved, Investigational Phase 3 65277-42-1 3823 47576
35
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
36 Antiparasitic Agents Phase 3,Phase 2
37 Antiprotozoal Agents Phase 3,Phase 2
38 Liposomal amphotericin B Phase 3,Phase 2
39
Aluminum hydroxide Approved, Investigational Phase 1, Phase 2 21645-51-2
40 Adjuvants, Immunologic Phase 1, Phase 2
41 Antacids Phase 1, Phase 2
42 Anti-Ulcer Agents Phase 1, Phase 2
43 Gastrointestinal Agents Phase 1, Phase 2
44 Vaccines Phase 1, Phase 2
45 Acidophilus Nutraceutical Phase 1,Early Phase 1
46
Iron Approved 7439-89-6 23925
47
Itraconazole Approved, Investigational 84625-61-6 55283
48
Metronidazole Approved 443-48-1 4173
49 Hydroxyitraconazole
50 Micronutrients

Interventional clinical trials:

(show all 46)

# Name Status NCT ID Phase Drugs
1 Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis Completed NCT02248506 Phase 4
2 Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Completed NCT02242695 Phase 4 Fluomizin vaginal tablets;Canesten vaginal tablets
3 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis Completed NCT02180828 Phase 4 Clotrimazole vaginal tablet;Fluconazole
4 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis Completed NCT02180100 Phase 4 Terconazole Vaginal Suppository;Fluconazole
5 Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Completed NCT00194324 Phase 4 Miconazole nitrate
6 Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections Recruiting NCT02860845 Phase 4 Antibiotic (Clindamycin);Antifungal (Clotrimazole)
7 Vaginal Infection Study Completed NCT00616330 Phase 3 clindamycin phosphate/butoconazole nitrate;clindamycin phosphate;butoconazole nitrate
8 Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis Completed NCT02251093 Phase 3 Lcr Regenerans;Placebo
9 The Study Of Fluconazole For Vulvovaginal Candidiasis Completed NCT01806623 Phase 3 Fluconazole
10 Comparative Efficacy of Ovule vs Tablet Completed NCT00755053 Phase 3 Clotrimazole, vaginal ovule;Clotrimazole, vaginal tablet
11 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) Completed NCT01293643 Phase 3 100 mg clindamycin /800 mg ketoconazole vaginal ovule;100 mg tetracycline hydrochloride /50 mg amphotericin B cream
12 Diabetes Mellitus and Vulvovaginal Candidiasis Completed NCT00353561 Phase 3 Boric;Fluconazole
13 ProF-001_Phase IIa Recruiting NCT03115073 Phase 2, Phase 3 Candiplus;Clotrimazole
14 Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream. Not yet recruiting NCT03005353 Phase 2, Phase 3 Cumin seed extract;clotrimazole
15 Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis Not yet recruiting NCT02907307 Phase 3 Clotrimazole vaginal tablet 100mg
16 Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC) Completed NCT02971007 Phase 2 Oral Encochleated Amphotericin B (CAMB);Fluconazole
17 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections Completed NCT02733432 Phase 2 CD101 Vaginal Gel (3%);CD101 External gel (1%);CD101 Vaginal Ointment (6%);CD101 External ointment (1%);Fluconazole
18 TOL-463 Phase 2 Study for Vaginitis Completed NCT02866227 Phase 2 TOL-463;TOL-463
19 Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Completed NCT02679456 Phase 2 SCY-078;Fluconazole
20 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) Completed NCT02267382 Phase 2 VT-1161;Placebo
21 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Completed NCT01926028 Phase 1, Phase 2
22 A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection) Completed NCT01891331 Phase 2 VT-1161 (oral);Fluconazole (oral)
23 MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis Completed NCT01497223 Phase 2 MGCD290
24 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Completed NCT01144286 Phase 2 arasertaconazole nitrate;placebo
25 An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis Recruiting NCT03253094 Phase 2 Fluconazole;SCY-078
26 Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis Not yet recruiting NCT03167957 Phase 2 Oral Encochleated Amphotericin B (CAMB);Oral Encochleated Amphotericin B (CAMB)
27 Patients With Vulvovaginal Candidiasis Not yet recruiting NCT03024502 Phase 1, Phase 2 EPP-AF Gel 1%;EPP-AF Gel 2%;Clotrimazole
28 Efficacy Vulvovaginitis Candida Terminated NCT00199264 Phase 2 Albaconazole oral solution
29 Use of Oral Probiotics as an Adjunctive Therapy to Fluconazole in the Treatment of Yeast Vaginitis Unknown status NCT00479947 Phase 1 Probiotics (Natural product);Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)
30 Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation Completed NCT02730494 Phase 1
31 Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection Completed NCT01067131 Phase 1
32 Maternal and Perinatal Outcome in Women With History of Premature Labor in Previous Pregnancy Completed NCT01375439
33 A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations Completed NCT01039584 Butoconazole Nitrate Vaginal Cream;Placebo;Gynazole 1 vaginal cream
34 Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) Completed NCT00895453 itraconazole;lactobacillus gasseri;classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
35 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis Completed NCT00803738 Terconazole Vaginal Suppository;Terazol Vaginal Suppository
36 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization Completed NCT02888197
37 Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis Completed NCT02203942
38 Observational Program Neo-Penotran® Forte Completed NCT01335373 Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)
39 Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Completed NCT02150655 Early Phase 1
40 Epidemiological Study in Subjects With Vulvovaginal Candidiases Recruiting NCT03064789
41 Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis Recruiting NCT02859493
42 Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women Recruiting NCT01915251
43 Women's Improvement of Sexual Health (WISH) Demonstration Project Active, not recruiting NCT03045809
44 Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial Not yet recruiting NCT03075046
45 Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M® Terminated NCT00915629
46 Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis Terminated NCT02345096

Search NIH Clinical Center for Vulvovaginitis

Cochrane evidence based reviews: vulvovaginitis

Genetic Tests for Vulvovaginitis

Anatomical Context for Vulvovaginitis

MalaCards organs/tissues related to Vulvovaginitis:

38
Testes, Colon, Neutrophil, Skin, B Cells, Ovary, Lymph Node

Publications for Vulvovaginitis

Articles related to Vulvovaginitis:

(show top 50) (show all 790)
# Title Authors Year
1
An unusual presentation of pseudocowpox associated with an outbreak of pustular ulcerative vulvovaginitis in a Swedish dairy herd. ( 29153035 )
2018
2
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation. ( 29340981 )
2018
3
A nested-PCR strategy for molecular diagnosis of mollicutes in uncultured biological samples from cows with vulvovaginitis. ( 29191491 )
2018
4
Computer-aided diagnosis software for vulvovaginal candidiasis detection from Pap smear images. ( 28987021 )
2018
5
Parapoxviral vulvovaginitis in Holstein cows. ( 29429402 )
2018
6
Surface-modified mucoadhesive microgels as a controlled release system for miconazole nitrate to improve localized treatment of vulvovaginal candidiasis. ( 28986195 )
2018
7
Development, characterization, and in vitro-in vivo evaluation of polymeric nanoparticles containing miconazole and farnesol for treatment of vulvovaginal candidiasis. ( 29361177 )
2018
8
Novel Mechanism behind the Immunopathogenesis of Vulvovaginal Candidiasis: "Neutrophil Anergy". ( 29203543 )
2018
9
New evidence on oral L. plantarum P17630 product in women with history of recurrent vulvovaginal candidiasis (RVVC): a randomized double-blind placebo-controlled study. ( 29364495 )
2018
10
Effectiveness of Ageratina pichinchensis Extract in Patients with Vulvovaginal Candidiasis. A Randomized, Double-Blind, and Controlled Pilot Study. ( 28299831 )
2017
11
Characterization of virulence factors of vaginal and anal isolates of Candida albicans sequentially obtained from patients with vulvovaginal candidiasis in north-east Brazil. ( 28844452 )
2017
12
Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis ( 28688376 )
2017
13
Fungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital. ( 28511380 )
2017
14
Comparison of enzymatic activities in different Candida species isolated from women with vulvovaginitis. ( 28236530 )
2017
15
Cyproterone acetate in the treatment of oestrogen hypersensitivity vulvovaginitis. ( 28718897 )
2017
16
Prevalence of Candida albicans, Candida dubliniensis and Candida africana in pregnant women suffering from vulvovaginal candidiasis in Argentina. ( 28385421 )
2017
17
Probiotics for vulvovaginal candidiasis in non-pregnant women. ( 29168557 )
2017
18
Emergence of Candida glabrata in vulvovaginal candidiasis should be attributed to selective pressure or virulence ability? ( 28730269 )
2017
19
Stratum corneum lipid liposome-encapsulated panomycocin: preparation, characterization, and the determination of antimycotic efficacy against Candida spp. isolated from patients with vulvovaginitis in an in vitro human vaginal epithelium tissue model. ( 28831255 )
2017
20
Candida Vulvovaginitis and Vulvodynia: The Mystery Continues. ( 28836889 )
2017
21
Automatic diagnosis of vulvovaginal candidiasis from Pap smear images. ( 28419509 )
2017
22
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association to clinical findings. ( 28052314 )
2017
23
Recurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen? ( 28868834 )
2017
24
Vaginal Candida spp. genomes from women with vulvovaginal candidiasis. ( 28582496 )
2017
25
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. ( 28696240 )
2017
26
Candida vulvovaginitis: A store with a buttery and a show window. ( 27687503 )
2017
27
Comparison of two long-term gestagen regimens in the management of recurrent vulvovaginal candidiasis: A pilot study. ( 28066940 )
2017
28
Vulvovaginitis: Find the cause to treat it. ( 28322677 )
2017
29
Vulvovaginal candidiasis: Etiology, symptomatology and risk factors. ( 28314677 )
2017
30
Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso. ( 28939305 )
2017
31
Recurrent vulvovaginal candidiasis: A review of guidelines and recommendations. ( 28967688 )
2017
32
Candidiasis, Vaginal (Vulvovaginal Candidiasis) ( 29083806 )
2017
33
Recurrent vulvovaginal candidiasis. ( 28615397 )
2017
34
Clonal spread and azole-resistant mechanisms of non-susceptible Candida albicans isolates from vulvovaginal candidiasis patients in three Shanghai maternity hospitals. ( 29136186 )
2017
35
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. ( 28760590 )
2017
36
Efficacy of Histatin5 in a murine model of vulvovaginal candidiasis caused by Candida albicans. ( 28645176 )
2017
37
Corrigendum to "Comparison between Fluconazole with Oral Protexin Combination and Fluconazole in the Treatment of Vulvovaginal Candidiasis". ( 29279857 )
2017
38
Characterization and identification of microbial communities in bovine necrotic vulvovaginitis. ( 28093107 )
2017
39
Prevalence of Candida africana and Candida dubliniensis, in vulvovaginal candidiasis: First Turkish Candida africana isolates from vulvovaginal candidiasis. ( 28641919 )
2017
40
Vulvovaginitis and diabetes. ( 28065975 )
2017
41
Recurrent vulvovaginal candidiasis: A review of guideline recommendations. ( 28299777 )
2017
42
Vulvovaginitis- presentation of more common problems in pediatric and adolescent gynecology. ( 28927766 )
2017
43
Haemophilus influenzae vulvovaginitis associated with rhinitis caused by the same clone in a prepubertal girl. ( 28621044 )
2017
44
Recurrent vulvovaginal candidiasis. ( 28927765 )
2017
45
Is MBL serum concentration a reliable predictor for recurrent vulvovaginal candidiasis? ( 29110332 )
2017
46
Contribution of TLR2 pathway in the pathogenesis of vulvovaginal candidiasis. ( 28911197 )
2017
47
Molecular identification and antifungal susceptibility profile of<i>Candida</i>species isolated from patients with vulvovaginitis in Tehran, Iran. ( 29387119 )
2017
48
Vulvovaginal laceration as a risk factor for uterine disease in postpartum dairy cows. ( 27016827 )
2016
49
Vulvovaginal-gingival syndrome and esophageal involvement in lichen planus. ( 26585852 )
2016
50
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. ( 27073145 )
2016

Variations for Vulvovaginitis

Expression for Vulvovaginitis

Search GEO for disease gene expression data for Vulvovaginitis.

Pathways for Vulvovaginitis

Pathways related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 CCL11 CCL5 CXCL8 IL10
2
Show member pathways
12.98 CCL11 CCL5 CXCL8 IL10
3
Show member pathways
12.9 CCL11 CCL5 CXCL8 IL10
4
Show member pathways
12.41 CCL11 CXCL8 HSPD1 IL10
5
Show member pathways
12.16 CCL5 CXCL8 IL10
6
Show member pathways
12 CCL11 CCL5 CXCL8
7
Show member pathways
11.86 CCL11 CCL5 CXCL8
8 11.82 CXCL8 HSPD1 IL10
9
Show member pathways
11.56 CCL11 CCL5 CXCL8
10 11.49 CCL11 CXCL8 IL10
11 11.46 CXCL8 IL10
12 11.36 CCL11 IL10
13 11.29 CXCL8 HSPD1
14 11.21 CXCL8 IL10
15 11.17 CCL11 IL10
16 11.13 CCL11 CCL5 CXCL8
17 10.84 CCL5 CXCL8
18 10.82 CCL5 CXCL8 IL10
19 10.61 CCL11 CCL5 CXCL8 IL10
20 10.15 CCL11 CCL5 CXCL8 IL10

GO Terms for Vulvovaginitis

Cellular components related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 CCL11 CCL5 CXCL8 HSPD1 IL10

Biological processes related to Vulvovaginitis according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.71 CCL11 CCL5 CXCL8 IL10
2 chemotaxis GO:0006935 9.69 CCL11 CCL5 CXCL8
3 regulation of receptor activity GO:0010469 9.62 CCL11 CCL5 CXCL8 IL10
4 cellular response to tumor necrosis factor GO:0071356 9.61 CCL11 CCL5 CXCL8
5 positive regulation of endothelial cell proliferation GO:0001938 9.57 CCL11 IL10
6 monocyte chemotaxis GO:0002548 9.56 CCL11 CCL5
7 inflammatory response GO:0006954 9.56 CCL11 CCL5 CXCL8 IL10
8 B cell proliferation GO:0042100 9.55 HSPD1 IL10
9 cellular response to fibroblast growth factor stimulus GO:0044344 9.54 CCL5 CXCL8
10 positive regulation of macrophage activation GO:0043032 9.52 HSPD1 IL10
11 response to molecule of bacterial origin GO:0002237 9.49 CXCL8 IL10
12 negative regulation of G-protein coupled receptor protein signaling pathway GO:0045744 9.48 CCL5 CXCL8
13 neutrophil activation GO:0042119 9.46 CCL5 CXCL8
14 eosinophil chemotaxis GO:0048245 9.37 CCL11 CCL5
15 cellular response to interleukin-1 GO:0071347 9.33 CCL11 CCL5 CXCL8
16 chemokine-mediated signaling pathway GO:0070098 9.13 CCL11 CCL5 CXCL8
17 neutrophil chemotaxis GO:0030593 8.8 CCL11 CCL5 CXCL8

Molecular functions related to Vulvovaginitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.13 CCL11 CCL5 CXCL8
2 cytokine activity GO:0005125 8.92 CCL11 CCL5 CXCL8 IL10

Sources for Vulvovaginitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....